Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ALX Oncology Holdings Inc. - Common Stock (NQ:ALXO)

0.4789 +0.0699 (+17.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 792,318
Open 0.4200
Bid (Size) 0.4600 (1)
Ask (Size) 0.4750 (10)
Prev. Close 0.4090
Today's Range 0.4199 - 0.4800
52wk Range 0.4051 - 15.35
Shares Outstanding 40,869,135
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
From ALX Oncology
Via GlobeNewswire

Performance

YTD
-69.3%
-69.3%
1 Month
-19.2%
-19.2%
3 Month
-57.2%
-57.2%
6 Month
-62.9%
-62.9%
1 Year
-96.8%
-96.8%

More News

Read More
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
Earnings Scheduled For May 8, 2025
Via Benzinga
What's Next: ALX Oncology Holdings's Earnings Preview
Via Benzinga
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
From ALX Oncology
Via GlobeNewswire
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
Which stocks are moving on Thursday?
Via Chartmill
Top movers in Thursday's session
Via Chartmill
This Zscaler Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
From ALX Oncology
Via GlobeNewswire
Earnings Scheduled For March 6, 2025
Via Benzinga
ALX Oncology to Host Virtual R&D Day on March 5, 2025
From ALX Oncology
Via GlobeNewswire
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
From ALX Oncology
Via GlobeNewswire

Frequently Asked Questions

Is ALX Oncology Holdings Inc. - Common Stock publicly traded?
Yes, ALX Oncology Holdings Inc. - Common Stock is publicly traded.
What exchange does ALX Oncology Holdings Inc. - Common Stock trade on?
ALX Oncology Holdings Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ALX Oncology Holdings Inc. - Common Stock?
The ticker symbol for ALX Oncology Holdings Inc. - Common Stock is ALXO on the Nasdaq Stock Market
What is the current price of ALX Oncology Holdings Inc. - Common Stock?
The current price of ALX Oncology Holdings Inc. - Common Stock is 0.4789
When was ALX Oncology Holdings Inc. - Common Stock last traded?
The last trade of ALX Oncology Holdings Inc. - Common Stock was at 05/22/25 04:00 PM ET
What is the market capitalization of ALX Oncology Holdings Inc. - Common Stock?
The market capitalization of ALX Oncology Holdings Inc. - Common Stock is 19.57M
How many shares of ALX Oncology Holdings Inc. - Common Stock are outstanding?
ALX Oncology Holdings Inc. - Common Stock has 20M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.